In a phase 2 study that aggressively de-escalated adjuvant RT for resected, HPV+ oropharyngeal cancer, what was the rate of locoregional control at 5 years?
A dosimetric analysis of de-escalated elective neck dosing for HNSCC found what two OARs saw the most significant reduction in dose?
In EC-CRT-002, did maintenance PD-1 inhibitor improve PFS following definitive CRT for unresectable esophageal SCC?
In a Japanese cohort of patients treated with up to 3 cycles of the quad shot regimen for HNSCC, what proportion of patients had stable or improved QOL at 3 months out?
Answers 98% with no local failures, even when the primary site was omitted in 52% of patients.
Contralateral parotid (-40%) and the larynx (-33%) with 30 Gy to elective volumes.
No. The interesting thing was that PFS was better than historical control in the arm that only received tislelizumab with neoadjuvant and concurrent chemo, not maintenance therapy.
80%. And most (81%) completed all three cycles of 3.5-3.7 Gy x 4 over 2 days every 3-6 weeks. | QuadShot News
A dosimetric analysis of de-escalated elective neck dosing for HNSCC found what two OARs saw the most significant reduction in dose?
In EC-CRT-002, did maintenance PD-1 inhibitor improve PFS following definitive CRT for unresectable esophageal SCC?
In a Japanese cohort of patients treated with up to 3 cycles of the quad shot regimen for HNSCC, what proportion of patients had stable or improved QOL at 3 months out?
Answers 98% with no local failures, even when the primary site was omitted in 52% of patients.
Contralateral parotid (-40%) and the larynx (-33%) with 30 Gy to elective volumes.
No. The interesting thing was that PFS was better than historical control in the arm that only received tislelizumab with neoadjuvant and concurrent chemo, not maintenance therapy.
80%. And most (81%) completed all three cycles of 3.5-3.7 Gy x 4 over 2 days every 3-6 weeks. | QuadShot News